Literature DB >> 3898491

Pharmacokinetics and nephrotoxicity of cyclosporine in renal transplant recipients.

F C Henny, C H Kleinbloesem, A J Moolenaar, L C Paul, D D Breimer, L A van Es.   

Abstract

Pharmacokinetics of Cyclosporine (CsA) were studied in 14 renal transplant patients during a three-month period of treatment. At 3 and 15 days after transplantation 12-hr blood level studies of the drug were performed to calculate the elimination half-life, area under the curve (AUC), and total blood clearance; trough levels were measured twice weekly. In 9 patients terminal half-lives could be calculated after discontinuation of CsA treatment. In the course of CsA treatment, prolongation of half-life was found in most cases, with a significant decrease in clearance (46 +/- 17 L/hr on day 3 versus 28 +/- 10 L/hr on day 15). This resulted in a continuous increase in the CsA blood level. The terminal half-life varied considerably among the patients (24-93 hr) and did not correlate with other pharmacokinetic parameters. A good correlation (r = 0.9589) was observed between CsA trough levels before discontinuation of CsA and the increment in renal function two weeks after conversion to azathioprine. This indicates that short-term CsA treatment induces a dose-dependent reversible nephrotoxic effect in renal transplant recipients.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3898491     DOI: 10.1097/00007890-198509000-00008

Source DB:  PubMed          Journal:  Transplantation        ISSN: 0041-1337            Impact factor:   4.939


  7 in total

1.  Comparison of methods to calculate cyclosporine A bioavailability from consecutive oral and intravenous doses.

Authors:  M O Karlsson; A Lindberg-Freijs
Journal:  J Pharmacokinet Biopharm       Date:  1990-08

2.  Prognostic value of T lymphocyte subset ratios for renal transplant survival in patients on different immunosuppressive regimens.

Authors:  F C Henny; A van Es; P J Oljans; W M Baldwin; H J Tanke; L A van Es; L C Paul
Journal:  Clin Exp Immunol       Date:  1986-08       Impact factor: 4.330

3.  Effect of cyclosporin on serum creatinine in patients with rheumatoid arthritis.

Authors:  B A Dijkmans; A W van Rijthoven; H S Goei The; Z L Montnor-Beckers; P C Jacobs; A Cats
Journal:  Eur J Clin Pharmacol       Date:  1987       Impact factor: 2.953

Review 4.  The Many Faces of Calcineurin Inhibitor Toxicity-What the FK?

Authors:  Samira S Farouk; Joshua L Rein
Journal:  Adv Chronic Kidney Dis       Date:  2020-01       Impact factor: 3.620

Review 5.  Immunosuppression for in vivo research: state-of-the-art protocols and experimental approaches.

Authors:  Rita Diehl; Fabienne Ferrara; Claudia Müller; Antje Y Dreyer; Damian D McLeod; Stephan Fricke; Johannes Boltze
Journal:  Cell Mol Immunol       Date:  2016-10-10       Impact factor: 11.530

Review 6.  Lessons to Learn From Low-Dose Cyclosporin-A: A New Approach for Unexpected Clinical Applications.

Authors:  Camila Flores; Guillemette Fouquet; Ivan Cruz Moura; Thiago Trovati Maciel; Olivier Hermine
Journal:  Front Immunol       Date:  2019-03-28       Impact factor: 7.561

Review 7.  Refining the Role of Simultaneous Liver Kidney Transplantation.

Authors:  Sabiha M Hussain; Kalathil K Sureshkumar
Journal:  J Clin Transl Hepatol       Date:  2018-06-08
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.